Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system


Main idea: Omnipod System use was associated with statistically and clinically meaningful reductions in Hemoglobin A1c(HbA1c)e A1c(HbA1c), TDD, and HE compared to prior treatments in T2DM.


To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems.

In this retrospective observational study (N = 3,592) the change in Hemoglobin A1c(HbA1c)e A1c(HbA1c) level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE, <70 mg/dL, n = 2,922) were assessed overall and by prior treatment modality (multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)), age group, and baseline Hemoglobin A1c(HbA1c)e A1c(HbA1c) category.


Please enter your comment!
Please enter your name here